1. Home
  2. NUWE vs ARTL Comparison

NUWE vs ARTL Comparison

Compare NUWE & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuwellis Inc.

NUWE

Nuwellis Inc.

HOLD

Current Price

$2.06

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$1.58

Market Cap

3.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUWE
ARTL
Founded
1999
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
3.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NUWE
ARTL
Price
$2.06
$1.58
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$30.00
AVG Volume (30 Days)
47.0K
1.2M
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,167,999.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.02
$1.48
52 Week High
$70.14
$28.60

Technical Indicators

Market Signals
Indicator
NUWE
ARTL
Relative Strength Index (RSI) 39.14 33.54
Support Level $2.02 $1.48
Resistance Level $2.35 $1.77
Average True Range (ATR) 0.18 0.16
MACD -0.01 0.02
Stochastic Oscillator 4.76 16.67

Price Performance

Historical Comparison
NUWE
ARTL

About NUWE Nuwellis Inc.

Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: